S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

AUTL Autolus Therapeutics PLC

2.22

0.00 (0.00%)

Jan 17 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics PLC News

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Friday 17 January 2025 (4 days ago) • GlobeNewswire Inc.

Autolus Therapeutics Provides Business Updates and 2025 Overview
Monday 13 January 2025 (1 week ago) • GlobeNewswire Inc.

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Monday 9 December 2024 (1 month ago) • GlobeNewswire Inc.

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
Monday 2 December 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 12 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 12 November 2024 (2 months ago) • Edgar (US Regulatory)

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Tuesday 12 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 12 November 2024 (2 months ago) • Edgar (US Regulatory)

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Friday 8 November 2024 (2 months ago) • GlobeNewswire Inc.

More Autolus Therapeutics PLC News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions